• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sat, 17.05.25

Search results


December 2024
Maamoun Basheer MD PhD, Nimer Assy MD

Takotsubo cardiomyopathy (TC) is a temporary and reversible hypokinesia of the left ventricle's apical area of the heart mediating systolic abnormality. This phenomenon resembles myocardial infarction but without coronary artery disease (CAD) [1]. The prevalence is 1.0–2.5% annually. Most of the patients with TC are postmenopausal women [2]. Over-stimulation of the sympathetic system, microvascular and myocardial tissue metabolism abnormality, and coronary artery vasospasm are linked to TC [2]. The criterion of the diagnosis consists of temporary hypokinesis or akinesis in left ventricle segments with or without apical involvement, electrocardiogram (ST-segment elevation and/or T-wave inversion), or significant elevation of serum cardiac troponins and non-existence of pheochromocytoma or myocarditis [3]. The pathognomonic finding of TC during echocardiography is apical ballooning involving the left ventricle. This unique morphology was reported to present in 75% of patients [2,3]. In 25% of patients. The morphology was reported to follow a mid-ventricular ballooning pattern due to mid-LV akinesis with no disturbance of apical and basal contraction [2,3].

November 2022
Maamoun Basheer PhD MD, Elias Saad MD, Faris Milhem MD, Dmitry Budman MD, Nimer Assy MD

Coronavirus disease 2019 (COVID-19) affects different people in different ways. Most infected people develop mild to moderate illness and recover without hospitalization. This case report presents a patient who had difficulty eradicating the corona virus due to being treated with rituximab, which depletes B lymphocytes and therefore disables the production of neutralizing antibodies. The regen-COV-2 antibody cocktail consists of two monoclonal antibodies, casirivimab and imdevimab. This cocktail successfully helped the patient's immune system eradicate the virus without auto specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production. In vitro studies confirm that eradication of the intact the virus. This case report emphases the importance of providing external antiviral antibodies regularly, like the regen-COV-2 antibody cocktail, as post- and even pre- SARS-CoV-2 infection prophylaxis in patients treated with rituximab.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel